<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00305396</url>
  </required_header>
  <id_info>
    <org_study_id>031041</org_study_id>
    <nct_id>NCT00305396</nct_id>
  </id_info>
  <brief_title>Calcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplantation</brief_title>
  <official_title>Calcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplant Recipients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <brief_summary>
    <textblock>
      A prospective, single center, open-label, randomized trial of Thymoglobulin induction and&#xD;
      sirolimus, prednisone, and mycophenolate mofetil versus Thymoglobulin induction and&#xD;
      tacrolimus, prednisone, and mycophenolate mofetil in non-HLA identical living or deceased&#xD;
      donor kidney transplant recipients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Calcineurin inhibitor-associated nephrotoxicity may exacerbate chronic allograft nephropathy&#xD;
      and reduce long-term kidney graft survival. Complete avoidance of calcineurin inhibitors may&#xD;
      improve graft function as measured by serum creatinine and calculated GFR and improve&#xD;
      long-term outcomes following kidney transplantation. We conducted a prospective, randomized,&#xD;
      single-center study comparing sirolimus versus tacrolimus in kidney transplantation. Primary&#xD;
      cadaver of non-HLA identical living donor recipients are randomized to received either&#xD;
      sirolimus 5 mg QD (target level 8-12 ng/ml) or tacrolimus 0.075 mg/kg BID (target level 8-12&#xD;
      ng/ml). All patients also received Thymoglobulin 1.5 mg/kg x 4 doses, mycophenolate 1 gm BID,&#xD;
      and prednisone. Main outcome measures are patient and graft survival, biopsy-proven acute&#xD;
      rejection, serum creatinine, hyperlipidemia, post-transplant diabetes, and surgical and wound&#xD;
      complications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date>March 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient and graft survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Biopsy proven acute rejection</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum creatinine</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hyperlipidemia</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>post-transplant diabetes</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>wound infections</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lymphoceles</measure>
  </secondary_outcome>
  <enrollment>80</enrollment>
  <condition>Kidney Transplantation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Primary cadaver or non-HLA identical living donor kidney transplant. -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        HIV HCV Pregnancy Age &lt; 18 years Malignancy&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Tarik Kizilisik, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center/Nashville VA</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Flechner SM, Goldfarb D, Modlin C, Feng J, Krishnamurthi V, Mastroianni B, Savas K, Cook DJ, Novick AC. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation. 2002 Oct 27;74(8):1070-6.</citation>
    <PMID>12438948</PMID>
  </reference>
  <verification_date>March 2006</verification_date>
  <study_first_submitted>March 20, 2006</study_first_submitted>
  <study_first_submitted_qc>March 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2006</study_first_posted>
  <last_update_submitted>March 20, 2006</last_update_submitted>
  <last_update_submitted_qc>March 20, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2006</last_update_posted>
  <keyword>Kidney transplantation</keyword>
  <keyword>immunosuppression</keyword>
  <keyword>sirolimus</keyword>
  <keyword>Thymoglobulin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

